Probiotic Strains for Gut Repair

The probiotic supplement market is dominated by generic multi-strain formulations marketed for general gut health, but the clinical evidence is not generic — it is strain-specific. The differences between two Lactobacillus rhamnosus strains can be larger than the differences between Lactobacillus and Bifidobacterium. The clinical literature has identified a small number of specific strains with strong evidence for specific indications: Lactobacillus rhamnosus GG (the ATCC 53103 strain isolated by Gorbach and Goldin) for acute and antibiotic-associated diarrhea, Saccharomyces boulardii CNCM I-745 (the only commercial yeast probiotic) for Clostridioides difficile and traveler's diarrhea, the VSL#3 / Visbiome eight-strain high-CFU formulation for ulcerative colitis and pouchitis, and Bifidobacterium longum 35624 (originally marketed as Align) for IBS. This deep-dive walks through the strain-by-strain evidence base, the practical CFU dosing, the post-antibiotic recolonization window, the contraindications in immunocompromise, and the distinction between probiotic supplements and fermented foods.

Table of Contents

  1. Why Strain-Specific Evidence Matters
  2. Lactobacillus rhamnosus GG (LGG)
  3. Saccharomyces boulardii CNCM I-745
  4. VSL#3 / Visbiome (Eight-Strain High-CFU)
  5. Bifidobacterium longum 35624 (Align)
  6. Other Strains with Meaningful Evidence
  7. CFU Dosing and Practical Use
  8. The Post-Antibiotic Recolonization Window
  9. Fermented Foods vs Probiotic Supplements
  10. Cautions and Contraindications
  11. Key Research Papers
  12. Connections

Why Strain-Specific Evidence Matters

Bacterial taxonomy is hierarchical: genus → species → strain. A bacterial strain is a specific isolate of a species with a characterized genome and phenotype, typically identified by alphanumeric designation (e.g., GG, 35624, NCFM, BB-12). The differences between strains of the same species can be enormous — gene content can vary by 20-30% between strains, and clinical effects vary correspondingly.

The International Scientific Association for Probiotics and Prebiotics (ISAPP) defines probiotics as "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host." The "adequate amounts" and "health benefit" are both strain-specific. A claim like "Lactobacillus acidophilus is good for digestion" is scientifically empty — the meaningful claim is "L. acidophilus NCFM at 10 billion CFU/day reduced bloating in patients with functional dyspepsia in trial X."

Practical implications for selecting a probiotic:

Back to Table of Contents

Lactobacillus rhamnosus GG (LGG)

Lactobacillus rhamnosus GG (also designated ATCC 53103) is the most extensively studied probiotic strain in the world — over 1,000 published trials and observational studies. The strain was isolated in 1985 by Sherwood Gorbach and Barry Goldin at Tufts University (the "GG" stands for Gorbach-Goldin) from the gastrointestinal tract of a healthy human volunteer.

The major LGG indications with strong evidence:

The dose used in most clinical trials is 10-20 billion CFU per day, typically as one or two divided doses. LGG is acid-stable and bile-stable, surviving stomach passage well. It does not permanently colonize the gut — transit time studies show it disappears from stool within 1-2 weeks of discontinuation. The clinical effect is therefore dependent on continuous administration.

Commercial products: Culturelle (the original LGG product, OTC at major US pharmacies), as a component of Visbiome / VSL#3, and in many multi-strain formulations from clinical brands.

Back to Table of Contents

Saccharomyces boulardii CNCM I-745

Saccharomyces boulardii is the only yeast probiotic with rigorous clinical evidence. It was isolated in 1923 by French microbiologist Henri Boulard from lychee fruit in Indochina (now Vietnam), after he observed that the local population brewed a lychee tea to treat cholera-related diarrhea. The CNCM I-745 strain (sold in the US as Florastor, Jarrow Saccharomyces Boulardii, and many other brands) is the strain with the published clinical evidence base.

Because S. boulardii is a yeast rather than a bacterium, it is intrinsically resistant to antibacterial antibiotics — making it the ideal probiotic to take alongside an antibiotic course without antibiotic killing the supplement. Its mechanism is multifactorial: it secretes a 54 kDa protease that cleaves Clostridioides difficile toxin A, it stimulates secretory IgA production, it competitively inhibits adhesion of pathogenic bacteria, and it stimulates short-chain fatty acid production by other commensals.

Major indications with strong evidence:

Dosing: typical clinical dose is 250-500 mg twice daily (one 250 mg capsule contains approximately 5 billion CFU). For C. difficile prevention alongside antibiotics, start with the first antibiotic dose and continue for 1 week after antibiotic completion.

Back to Table of Contents

VSL#3 / Visbiome (Eight-Strain High-CFU)

VSL#3 is a high-CFU multi-strain formulation containing eight bacterial strains: four Lactobacillus (L. plantarum, L. paracasei, L. acidophilus, L. delbrueckii subsp. bulgaricus), three Bifidobacterium (B. breve, B. longum, B. infantis), and one Streptococcus (S. thermophilus). Total CFU is 450 billion per sachet (the prescription-strength version) or 112.5 billion per capsule (the consumer-grade version).

The history is complicated. The original formulation was developed by Italian gastroenterologist Claudio De Simone, who licensed it through a series of corporate arrangements that resulted in litigation between him and the original VSL#3 distributor. As of 2016, the original De Simone Formulation is sold as Visbiome in North America, while the "VSL#3" trademark continues to be used for a reformulated product that may not contain the identical strains. For trial replication, the De Simone Formulation = Visbiome is the formulation that produced the published clinical results.

Major indications with strong evidence:

Dosing: in active ulcerative colitis, the trial dosing is 900 billion CFU per day (2 sachets BID). For maintenance, 450 billion CFU per day. For pouchitis maintenance, 450-900 billion CFU per day. These doses are far higher than typical OTC probiotics, which is part of the clinical efficacy story — the high CFU saturates the colon and produces measurable changes in fecal short-chain fatty acid production.

Back to Table of Contents

Bifidobacterium longum 35624 (Align)

Bifidobacterium longum 35624 is the strain with the strongest IBS evidence in any monostrain formulation. It was developed at the Alimentary Pharmabiotic Centre at University College Cork by Eamonn Quigley and colleagues, originally isolated from a healthy human gastrointestinal tract. The Whorwell et al. 2006 trial published in American Journal of Gastroenterology randomized 362 women with IBS to one of three doses of B. infantis 35624 (later reclassified as B. longum 35624 after taxonomic revision) or placebo for 4 weeks. The 1 billion CFU/day dose produced significant improvement in abdominal pain/discomfort, bloating/distension, and bowel-habit satisfaction compared with placebo.

Subsequent studies have confirmed the effect and identified the likely mechanism: B. longum 35624 reduces pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1) and increases regulatory cytokines (IL-10), shifting the gut immune set-point toward tolerance.

Commercial product: originally sold as Align in the US (Procter & Gamble), available OTC. The labeled dose is 1 billion CFU per capsule, taken once daily. Onset of clinical effect typically requires 4-6 weeks of daily use.

Indications:

Back to Table of Contents

Other Strains with Meaningful Evidence

Back to Table of Contents

CFU Dosing and Practical Use

Clinical trial CFU dosing varies enormously by strain and indication:

Practical timing: most probiotics are best taken with food (the buffering effect of food on stomach acid increases survival through stomach passage). Exception: S. boulardii, which is intrinsically acid-stable and can be taken any time. For high-CFU multi-strain formulations, splitting the daily dose into 2-3 administrations may improve colonization saturation.

CFU degradation between manufacture and consumption is the biggest source of OTC probiotic underdosing. Many products are labeled at manufacture CFU; by the time of consumption (after warehouse, shipping, retail storage, home storage), actual CFU may be 10-50% of label. Look for products labeled "CFU guaranteed through expiration date" and that specify refrigeration requirements clearly.

Back to Table of Contents

The Post-Antibiotic Recolonization Window

Antibiotics reduce gut microbial diversity dramatically — broad-spectrum antibiotic courses (clindamycin, cephalosporins, fluoroquinolones) can reduce gut bacterial CFU by 2-3 log within days. Recovery is partial and often incomplete: trials of stool microbiome 6 months after a single antibiotic course typically show persistent loss of approximately 10-20% of the pre-antibiotic species, with the lost organisms not returning even at 1 year follow-up.

The post-antibiotic period is therefore both a window of risk (dysbiosis, C. difficile susceptibility, opportunistic overgrowth) and a window of opportunity (the relatively empty niche may be more receptive to colonization by deliberately introduced strains). Standard recommendations:

An emerging research area is autologous fecal microbiota transplantation — storing one's own stool before a planned antibiotic course (e.g., before elective surgery, chemotherapy) and reinstating it afterward via colonoscopy. Early trial evidence (Taur et al. 2018, Suez et al. 2018) supports this approach for restoring pre-antibiotic microbiome composition, but autologous FMT is not yet commercially available outside research settings.

Back to Table of Contents

Fermented Foods vs Probiotic Supplements

Fermented foods (sauerkraut, kimchi, kefir, yogurt, kombucha, miso, natto, tempeh) and probiotic supplements are complementary, not interchangeable.

Probiotic supplements:

Fermented foods:

Practical recommendation: use both. Daily fermented foods (1-2 servings of properly fermented sauerkraut, kimchi, kefir, or yogurt) for diversity. Targeted probiotic supplement matched to specific indication (LGG for AAD, S. boulardii alongside antibiotics, VSL#3/Visbiome for UC, B. longum 35624 for IBS, etc.).

Back to Table of Contents

Cautions and Contraindications

Back to Table of Contents

Key Research Papers

  1. Szajewska H, Kolodziej M (2015). Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. — PubMed
  2. McFarland LV (2010). Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. — PubMed
  3. Gionchetti P et al. (2000). Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. — PubMed
  4. Tursi A et al. (2010). Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment. Am J Gastroenterol. — PubMed
  5. Whorwell PJ et al. (2006). Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. — PubMed
  6. Goldenberg JZ et al. (2017). Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database. — PubMed
  7. Hill C et al. (2014). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. — PubMed
  8. Suez J et al. (2018). Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. — PubMed
  9. Wastyk HC et al. (2021). Gut-microbiota-targeted diets modulate human immune status. Cell. — PubMed
  10. Besselink MG et al. (2008). Probiotic prophylaxis in predicted severe acute pancreatitis: PROPATRIA. Lancet. — PubMed
  11. Doron S, Snydman DR (2015). Risk and safety of probiotics. Clin Infect Dis. — PubMed
  12. Miele E et al. (2009). Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents